Human Insulin as an Antidote to the High Cost of Insulin: Clinical Insignificance of Pharmacokinetic/Pharmacodynamic Differences.

Abstract

Commentary| March 06 2023 Human Insulin as an Antidote to the High Cost of Insulin: Clinical Insignificance of Pharmacokinetic/Pharmacodynamic Differences Mayer B. Davidson 0000-0001-9194-8857 Mayer B. Davidson Charles R. Drew University, Los Angeles, CA Corresponding author: Mayer B. Davidson, mayerdavidson@cdrewu.edu Search for other works by this author on: This Site PubMed Google Scholar Corresponding author: Mayer B. Davidson, mayerdavidson@cdrewu.edu Clin Diabetes cd220106 https://doi.org/10.2337/cd22-0106 Views Icon Views Article contents Figures & tables Video Audio Supplementary Data Peer Review Share Icon Share Facebook Twitter LinkedIn MailTo Cite Icon Cite Get Permissions Citation Mayer B. Davidson; Human Insulin as an Antidote to the High Cost of Insulin: Clinical Insignificance of Pharmacokinetic/Pharmacodynamic Differences. Clin Diabetes 2023; cd220106. https://doi.org/10.2337/cd22-0106 Download citation file: Ris (Zotero) Reference Manager EasyBib Bookends Mendeley Papers EndNote RefWorks BibTex toolbar search Search Dropdown Menu toolbar search search input Search input auto suggest filter your search All ContentAll JournalsClinical Diabetes Search Advanced Search This content is only available via PDF. ©2023 by the American Diabetes Association2023Readers may use this article as long as the work is properly cited, the use is educational and not for profit, and the work is not altered. More information is available at https://www.diabetesjournals.org/journals/pages/license. Article PDF first page preview Close Modal You do not currently have access to this content.